GALMED PHARMACEUTICALS LTD (GLMD)

IL0011313900 - Common Stock

0.3871  +0.04 (+10.6%)

Fundamental Rating

2

GLMD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. While GLMD seems to be doing ok healthwise, there are quite some concerns on its profitability. GLMD does not seem to be growing, but still is valued expensively.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

GLMD had negative earnings in the past year.
GLMD had a negative operating cash flow in the past year.
In the past 5 years GLMD always reported negative net income.
GLMD had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

GLMD has a Return On Assets (-41.55%) which is comparable to the rest of the industry.
With a decent Return On Equity value of -49.78%, GLMD is doing good in the industry, outperforming 68.77% of the companies in the same industry.
Industry RankSector Rank
ROA -41.55%
ROE -49.78%
ROIC N/A
ROA(3y)-79.39%
ROA(5y)-63.92%
ROE(3y)-96.47%
ROE(5y)-76.78%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GLMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, GLMD has more shares outstanding
GLMD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for GLMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

GLMD has an Altman-Z score of -16.51. This is a bad value and indicates that GLMD is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of GLMD (-16.51) is worse than 84.64% of its industry peers.
GLMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.51
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

GLMD has a Current Ratio of 4.81. This indicates that GLMD is financially healthy and has no problem in meeting its short term obligations.
GLMD has a Current ratio (4.81) which is comparable to the rest of the industry.
A Quick Ratio of 4.81 indicates that GLMD has no problem at all paying its short term obligations.
GLMD has a Quick ratio of 4.81. This is comparable to the rest of the industry: GLMD outperforms 53.07% of its industry peers.
Industry RankSector Rank
Current Ratio 4.81
Quick Ratio 4.81

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.95% over the past year.
EPS 1Y (TTM)68.95%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q34.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, GLMD will show a small growth in Earnings Per Share. The EPS will grow by 7.47% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y59.64%
EPS Next 2Y29.53%
EPS Next 3Y18.97%
EPS Next 5Y7.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GLMD. In the last year negative earnings were reported.
Also next year GLMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as GLMD's earnings are expected to grow with 18.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.53%
EPS Next 3Y18.97%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GLMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GALMED PHARMACEUTICALS LTD

NASDAQ:GLMD (5/1/2024, 3:00:07 PM)

0.3871

+0.04 (+10.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.33M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.55%
ROE -49.78%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.81
Quick Ratio 4.81
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)68.95%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y59.64%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y